Skip to main content
LYSOGENE logo

LYSOGENE — Investor Relations & Filings

Ticker · LYS ISIN · FR0013233475 LEI · 969500T64RILK1RD0852 PA Professional, scientific and technical activities
Open in API
Filings indexed 254 across all filing types
Latest filing 2022-04-28 Earnings Release
Country FR France
Listing PA LYS

About LYSOGENE

https://www.lysogene.com

Lysogene was a clinical-stage biotechnology company that specialized in the research and development of gene therapies for rare, inherited neurodegenerative diseases affecting the central nervous system (CNS). The company's approach focused on delivering a functional copy of a deficient gene directly to the brain to address the root cause of the targeted disorder. Its pipeline included investigational treatments for lysosomal storage diseases such as Sanfilippo syndrome type A (MPS IIIA) and GM1 gangliosidosis. Following clinical and financial challenges, the company initiated judicial liquidation proceedings in 2023.

Recent filings

Filing Released Lang Actions
Information financière trimestrielle / Information financière du premier trimestre
Earnings Release Classification · 1% confidence The document is titled "COMMUNIQUE DE PRESSE" (Press Release) and its primary focus is announcing the company's cash position ('Trésorerie et équivalents de trésorerie') as of March 31, 2022. This type of announcement, which provides key financial highlights (cash balance, comparison to previous period, and management commentary on cash runway) immediately following a reporting period end, aligns perfectly with the definition of an Earnings Release (ER). It is not a comprehensive report (like 10-K or IR), nor is it a transcript (CT) or a formal presentation (IP). Since it is a direct announcement of financial results highlights, ER is the most appropriate classification. Q1 2022
2022-04-28 French
Quarterly financial reporting / First quarter financial report
Earnings Release Classification · 1% confidence The document is explicitly titled "PRESS RELEASE" and reports the company's "Cash Position as of 31 March 2022." It provides key financial highlights (€10.7 million cash) and management commentary on the cash runway, comparing it to the previous period (31 December 2021). This format—a brief, high-level announcement of period-end financial metrics—is characteristic of an Earnings Release (ER), which typically precedes the full Quarterly Report (IR) or Annual Report (10-K). Since it focuses only on the cash position and management outlook rather than comprehensive financial statements, ER is the most appropriate classification. The document length (4537 chars) is short, but it is the primary announcement, not just an announcement *of* a report. Q1 2022
2022-04-28 English
Inside Information / Other news releases
Earnings Release Classification · 1% confidence The document is explicitly titled "PRESS RELEASE" and announces "Positive Preliminary Preclinical Results in the Treatment of Fragile X Syndrome." It details scientific findings, references a peer-reviewed article publication, includes quotes from management, and contains a standard 'Forward Looking Statement' section typical of corporate news releases. This format strongly indicates an Earnings Release (ER) or a general press release announcing significant operational/scientific news. Since it is not a full quarterly/annual report (10-K or IR) or a transcript (CT), and it focuses on results/updates, ER is the most appropriate classification for a preliminary results announcement. It is not a formal regulatory filing like an RNS, but rather a specific type of corporate communication. FY 2022
2022-04-21 English
Informations privilégiées / Autres communiqués
Earnings Release Classification · 1% confidence The document is titled "COMMUNIQUÉ DE PRESSE" (Press Release) and announces positive preliminary preclinical results regarding a treatment for Fragile X Syndrome (FXS), referencing a published scientific article and including quotes from the Chief Scientific Officer. This format—a brief announcement of scientific/business progress, often including forward-looking statements and contact information—is characteristic of an Earnings Release (ER) or a general regulatory announcement. Since it is not a full financial report (10-K, IR), a transcript (CT), or a specific management/board change, and it is announcing key operational/scientific progress, it fits best under the Earnings Release category (ER) which often encompasses major operational updates, or potentially Regulatory Filings (RNS) if it were less focused on results. Given the focus on 'results' and the structure typical of quarterly/periodical updates, ER is the most appropriate fit among the specific options, although it is not strictly an earnings report. However, since it is a press release announcing scientific progress, it is a form of corporate communication that often accompanies or substitutes for an ER in biotech. If it were purely a scientific publication announcement without the context of a regular reporting cycle, RNS might apply, but ER is often used for major operational/scientific milestones announced via press release. FY 2022
2022-04-21 French
Modalités de mise à disposition de document de référence ou de ses actualisations
Report Publication Announcement Classification · 1% confidence The document is titled "COMMUNIQUE DE PRESSE" (Press Release) and its primary purpose is to announce that Lysogene has filed its 2021 Universal Registration Document ("URD") with the AMF (Autorité des Marchés Financiers) on April 19, 2022. The text explicitly states that the URD contains the Annual Financial Report, Management Report, and Corporate Governance Report. Since the document itself is an announcement about the publication/filing of other comprehensive reports, and not the reports themselves, it fits the definition of a Report Publication Announcement (RPA). The document length (4927 chars) is also consistent with a short announcement rather than a full annual report (10-K) or interim report (IR).
2022-04-20 French
Terms of availability of a registration document or its updates
Report Publication Announcement Classification · 1% confidence The document is titled "PRESS RELEASE" and its primary purpose is to announce that the company has "Announces Filing of 2021 Universal Registration Document (URD)" with the French market authority (AMF). The document itself is short (4266 characters) and primarily serves as a notification that the full report (which contains the annual financial report, management report, and corporate governance report) is now available elsewhere. According to Rule #2 (The "MENU VS MEAL" Rule), a short announcement stating a report has been published or is attached points towards a Report Publication Announcement (RPA) rather than the full report itself (like 10-K or IR). Since this is explicitly announcing the publication/filing of a major regulatory document, RPA is the most appropriate classification.
2022-04-20 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.